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Abstract
Purpose The prevalence of colorectal cancer is higher among patients with type 2 diabetes mellitus (T2D) than among patients
without diabetes. Furthermore, men are at higher risk for developing colorectal cancer than women in the general population and
also subsite-specific risks differ per sex. The aim was to evaluate the impact of T2D on these associations.
Methods A population-based matched cohort study was performed using data from the PHARMO Database Network. Patients
with T2D were selected and matched (1:4) to diabetes free controls. Cox proportional hazards models were used to estimate
hazard ratios (HRs) for CRC and its subsites. HRs were determined per sex and adjusted for age and socioeconomic status. The
ratio of distal versus proximal colon cancer was calculated for people with T2D and controls per sex and stratified by age.
Results Over 55,000 people with T2D were matched to > 215,000 diabetes free controls. Men and women with T2D were 1.3
times more likely to develop colorectal cancer compared to controls. Men with T2D were at higher risk to develop distal colon
cancer (hazard ratio (95% confidence interval), 1.42 (1.08–1.88)), and women with T2D were at higher risk for developing
proximal colon cancer (hazard ratio (95% confidence interval), 1.58 (1.13–2.19)). For rectal cancer, no statistically significant
risk was observed for both men and women.
Conclusions Sex-specific screening strategies and prevention protocols should be considered for people with T2D.More tailored
screening strategies may optimize the effectiveness of colorectal cancer screening in terms of reducing incidence and mortality.
Keywords Type 2 diabetes . Sidedness . Proximal colon cancer . Distal colon cancer . Right-sided colon cancer . Left-sided colon
cancer
Introduction
Type 2 diabetes mellitus (T2D) and colorectal cancer (CRC)
are increasing health problems. Currently, CRC is the third
most common cancer worldwide and the second most com-
mon cancer in Europe [1]. The number of people with CRC is
expected to increase due to demographic changes, obesity, and
lack of physical activity. Also, the prevalence of T2D is
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00384-018-3191-7) contains supplementary
material, which is available to authorized users.
* Jetty A. Overbeek
jetty.overbeek@pharmo.nl
1 Department of General Practice and Elderly Care Medicine,
Amsterdam Public Health Research Institute, VUUniversityMedical
Centre, Van der Boechorststraat 7, 1081 BTAmsterdam, Netherlands
2 PHARMO Institute for Drug Outcomes Research,
Utrecht, Netherlands
3 Department of Public Health, Erasmus University Medical Centre,
Rotterdam, Netherlands
4 Department of Medical Oncology, VU University Medical Center,
Amsterdam, Netherlands
5 Department of Clinical Epidemiology, Leibniz Institute for
Prevention Research and Epidemiology – BIPS, Bremen, Germany
6 Faculty of Human and Health Sciences, University of Bremen,
Bremen, Germany
7 Department of Epidemiology & Biostatistics, VU University
Medical Center, Amsterdam, Netherlands
International Journal of Colorectal Disease
https://doi.org/10.1007/s00384-018-3191-7
increasing worldwide [2, 3]. In the Netherlands, the preva-
lence of T2D more than doubled between 1999 and 2014,
mainly due to demographic changes, but probably also due
to overweight and screening initiatives [4].
Regardless of T2D, CRC incidence, prevalence, and mor-
tality are higher among men than women [5, 6]. However,
women aged ≥ 55 years are more often diagnosed with prox-
imal (right-sided) CRC [7], which is associated with more
aggressive form of neoplasia than distal (left-sided) CRC
[8]. Among these reasons, sex-specific screening strategies
have been proposed [9].
Several observational studies have demonstrated an in-
creased risk of CRC in people with T2D [10, 11]. Several mech-
anisms have been proposed to explain the higher prevalence of
CRC in people with hyperglycemia, such as hyperglycemia in
itself, hyperinsulinemia, which leads to increased insulin-like
growth factor (IGF) levels, and insulin resistance [12].
Some reviews and meta-analyses regarding the association
between T2D and CRC reported a higher risk of CRC among
women with T2D (compared to their disease-free controls)
[13] than among men with T2D (compared to their disease-
free controls) [14], while others concluded that the risk among
people with T2D compared to people without T2D is regard-
less of sex [15–18].
Sex-specific differences in risk of anatomical subsites of
CRC in people with T2D are less studied. As people with
T2D already undergo health check-ups regularly, it is impor-
tant to know whether sex-specific screening strategies would
also be necessary for people with T2D. Therefore, the aim of
the current study was to evaluate the sex-specific risk of sub-
sites of CRC in people with T2D compared to people without
diabetes in a population-based cohort. In this study, the unique
linkage between the General Practitioner (GP) Database of the
PHARMO Database Network and the Netherlands Cancer
Registry (NCR) was used, creating a comprehensive large
database with detailed and high-quality data on cancer and
T2D.
Material and Methods
Data sources
Data for this cohort study were obtained from the GP
Database of the PHARMO Database Network [19] and the
NCR. The GP Database comprises data from electronic pa-
tient records registered by GPs. The records include informa-
tion on diagnoses and symptoms, laboratory test results, refer-
rals to specialists, and healthcare product/drug prescriptions.
Currently, the GP Database covers a catchment area of ap-
proximately 3.5 million inhabitants. Recently, the GP
Database was linked to the NCR on a patient-level. The
NCR is maintained by the Netherlands Comprehensive
Cancer Organization (IKNL) [20] and contains information
on newly diagnosed patients with cancer, coded according to
the WHO International Classification of Diseases for
Oncology (ICD-O-3). The NCR is notified, on a daily basis,
for new patients with cancer by pathology departments, gen-
eral hospitals, and radiotherapy institutes. The construct of the
record linkage method is described elsewhere [21]. The priva-
cy committees of the NCR and the PHARMO Institute ap-
proved this study.
Study population
From PHARMO’s GP Database, all people diagnosed with
T2D between 2006 and 2014 were selected. T2D was defined
as a recorded episode for T2D or ≥ 2 prescriptions of a blood
glucose–lowering drug, excluding insulin, within a 6-month
period at any time in the available medication records. The
date of the first recorded episode for T2D, the second prescrip-
tion, or the first examination regarding diabetes, whichever
occurred first, was defined as the index date. People with
another type of diabetes, using insulin prior to index date, <
40 years of age at index date, or having a history of cancer
were excluded (see Supplementary Table S1 for codes used
for exclusion criteria). Patients with < 12 months of continu-
ous enrolment prior to index date were excluded as well, in
order to ensure newly diagnosed people with T2D.
People with T2D were randomly matched (1 up to 4) to
controls on sex, year of birth (± 2 years), GP practice, and start
year of enrolment in the database. Matched controls received
the same index date as their matched cases. Controls who had
a history of diabetes, were < 40 years of age at index date, had
< 12 months of continuous enrolment prior to index date, or
had a history of cancer were excluded. Furthermore, controls
had to be alive and known in the GP Database at index date
and could not be matched to themselves or more than once.
All people with T2D and matched controls were followed
from index date until diagnosis of CRC, diagnosis of (another
type of) diabetes, end of database registration (i.e., patient
moves out of the catchment area), death, or end of study pe-
riod (December 31, 2014), whichever occurred first.
Characteristics
For all included people, the following was determined at index
date: age, socioeconomic status (SES), available history and
follow-up in the database, and year of index date.
Furthermore, the use of aspirin, non-aspirin non-steroidal
anti-inflammatory drugs (NSAIDs), statins, antihypertensives,
and hormone replacement therapy (HRT) was determined in
the year prior to index date (see Supplementary Table S1 for
ATC codes). SES was derived from Statistics Netherlands
[22], which based SES on salary per 6-digit zip code deter-
mined in December 2008.
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Outcome
During follow-up, the occurrence of the initial diagnosis of
primary, localized (or non-metastatic) CRCwas obtained from
the NCR and used as outcome in the analyses. Proximal colon
cancers included malignant neoplasms of cecum, appendix,
ascending colon, hepatic flexure, and transverse colon.
Distal colon cancers included malignant neoplasms of splenic
flexure, descending colon, and sigmoid colon. Rectal cancer
included malignant neoplasm of rectum. Malignant neoplasm
of overlapping sites of colon, unspecified sites of colon, and
rectosigmoid junction were included when analyzing overall
CRC.
Statistical methods
Characteristics of all included people were reported descrip-
tively. Differences in characteristics between men and women
with T2D were compared with men and women without dia-
betes and assessed using chi-square tests for categorical vari-
ables and ANOVA tests for continuous variables.
Unadjusted incidence rates (IRs) for CRC were determined
by dividing the total number of events by the total number of
patient years at risk (summed number of years of follow-up).
To generate hazard ratios (HR) and their corresponding 95%
confidence intervals (CI), Cox proportional hazards model,
adjusted for age, SES, and drugs known to (potentially) influ-
ence risk of CRC (aspirin, non-aspirin NSAIDs, statins, anti-
hypertensives, and HRT) were used. The analyses were strat-
ified according to three categories regarding anatomic subsites
(proximal colon, distal colon, and rectum) and risk estimates
were also calculated for each subsite separately.
As several studies have reported a shift of CRC localization
by age [7], it was determined whether the same trend was
observed among people with T2D. The number of distal (in-
cluding rectal) colon cancers was divided by the number of
proximal colon cancers to calculate the ratio of distal versus
proximal colon cancer. This ratio was calculated for people
with T2D and no diabetes per sex and was stratified by age
(50–69 and ≥ 70 years) at index date.
All data were analyzed using SAS programs organized
within SAS Enterprise Guide version 4.3 (SAS Institute Inc.,
Cary, NC, USA) and conducted under Windows using SAS
version 9.2.
Sensitivity analyses
Reported associations in observational studies can be affected
by detection (protopathic) bias, i.e., an increased odds of de-
tecting cancer shortly after the onset of diabetes [10]. In order
to explore the extent of detection bias, the risk of (anatomic
subsites of) CRC was stratified by follow-up period (0–
91 days, > 91–182 days, > 182–365 days, and > 365 days).
Per follow-up period, people with the date of CRC not within
the follow-up period were censored. Only follow-up up to the
end of that specific follow-up period, end of follow-up, or date
of CRC, whichever occurred first, was used to calculate the
total number of patient years at risk.
Results
Patient characteristics
After applying all in- and exclusion criteria, 29,696 men and
25,349 women with T2D were included and matched to
116,570 and 99,437 diabetes free controls, respectively (see
Supplementary Fig. S1). Mean age at baseline was 62.1 years
among men and 64.9 years among women. Baseline charac-
teristics, such as age, SES, history in the database, and year of
index date, were similar between people with T2D and people
without diabetes. Available follow-up in the database was lon-
ger among cases compared to controls. Furthermore, people
with T2D more often used aspirin, non-aspirin NSAIDs,
statins, and antihypertensives compared to the matched people
without diabetes (see Table 1).
Colorectal cancer
Figure 1 and Table 2 present the subsite-specific rates of CRC
among men and women with T2D and their matched controls.
Supplementary Table S2 presents the number of CRC events
and person years at risk amongmen and women with T2D and
no diabetes. Overall, both men and women with T2Dwere 1.3
times more likely to develop CRC compared to their controls
without diabetes. However, differences regarding subsite-
specific risks were observed between the sexes. Compared
to diabetes free controls, men with T2D were at higher risk
to develop distal colon cancer (HR (95% CI), 1.42 (1.08–
1.88)) than women with T2D (HR (95% CI), 0.86 (0.55–
1.35)). The same trend was observed in the anatomical sub-
sites of distal colon cancer, except for cancer of the splenic
flexure. Again, compared to controls without diabetes, women
with T2D were at higher risk to develop proximal colon can-
cer (HR (95% CI), 1.58 (1.13–2.19)) than men with T2D (HR
(95% CI), 1.20 (0.87–1.65)). This difference was also ob-
served for all subsites of proximal colon cancer, although
not always statistically significant. Women with T2D had a
higher risk to develop rectal cancer than men with T2D com-
pared to diabetes free controls, but the risk in both men and
women was not statistically significant (HR (95%CI) for men
is 1.06 (0.77–1.47) and 1.33 (0.88–2.02) for women).
Figure 2 presents the ratio of distal (including rectal) versus
proximal colon cancer stratified by T2D status in men
(Fig. 2a) and women (Fig. 2b). As presented in Fig. 2a, distal
colon cancer is more frequent than proximal colon cancer (i.e.,
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ratio > 1) in men with T2D and no diabetes. The same is ob-
served in men aged ≥ 70 years; however the ratio is lower than
for men aged 50–69 years. As shown in Fig. 2b the ratio
among women is also above 1 (i.e., more distal than proximal
colon cancers), except for women with T2D aged ≥ 70 years,
i.e., these women are more likely to be diagnosed with
proximal colon cancer than with distal colon cancer.
Generally, the ratio was lower for women than for men, i.e.,
irrespective of age and T2D status.
Sensitivity analysis
To account for potential detection bias, risk of (anatomical
subsites of) CRC was stratified by follow-up period
(Supplementary Fig. S2). When considering a 1-year lag pe-
riod, the risk of overall CRC and its subsites was similar than
the risk calculated without a lag period; only the risk of distal
colon cancer became slightly lower through consideration of a
1-year lag period. The differences in risk between men and
women remained after applying the lag period.
Discussion and conclusion
In this population-based cohort study among more than
270.000 people, we observed a similarly increased risk of
CRC among men and women with T2D compared to diabetes
Table 1 General characteristics of people with T2D and no diabetes
Men Women
T2D N = 29,696
n (%)
No diabetes N = 116,570
n (%)
p value T2D N = 25,349
n (%)
No diabetes N = 99,437
n (%)
p value
Age (years), mean ± SD 62.1 ± 10.9 62.0 ± 10.9 0.06 64.9 ± 12.2 64.8 ± 12.2 0.10
SES 0.99 0.99
Low 7460 (25) 29,247 (25) 6570 (26) 25,722 (26)
Normal 9481 (32) 37,217 (32) 8281 (33) 32,507 (33)
High 12,755 (43) 50,106 (43) 10,498 (41) 41,208 (41)
Patient history in
database (years)
0.24 0.28
Mean ± SD 4.0 ± 2.1 4.1 ± 2.1 3.9 ± 2.1 4.0 ± 2.1
Median (IQR) 3.8 (2.2–5.6) 3.8 (2.2–5.7) .24 3.6 (2.2–5.4) 3.6 (2.2–5.5)
Follow-up in
database (years)
< .0001 < .0001
Mean ± SD 3.7 ± 2.2 3.5 ± 2.2 3.8 ± 2.2 3.7 ± 2.2
Median (IQR) 3.7 (1.9–5.5) 3.4 (1.7–5.3) 3.8 (2.0–5.6) 3.7 (1.8–5.5)
Year of index date 0.60 0.53
2007–2008 6205 (21) 24,691 (21) 5644 (22) 22,477 (23)
2009–2010 8528 (29) 33,612 (29) 7579 (30) 29,869 (30)
2011–2012 8059 (27) 31,447 (27) 6598 (26) 25,688 (26)
2013–2014 6904 (23) 26,820 (23) 5528 (22) 21,403 (22)
Co-medicationa
Aspirin 4972 (17) 12,303 (11) < .0001 3236 (13) 8197 (8) < .0001
Non-aspirin NSAIDs 6999 (24) 22,274 (19) < .0001 6594 (26) 22,092 (22) < .0001
Statins 11,626 (39) 22,828 (20) < .0001 8800 (35) 15,712 (16) < .0001
Antihypertensives 13,208 (44) 28,925 (25) < .0001 13,469 (53) 30,609 (31) < .0001
HRT – – 814 (3) 3656 (4) < .01
SD standard deviation, IQR interquartile range, NSAIDs non-steroidal anti-inflammatory drugs, HRT hormone replacement therapy,
a Determined in the year prior to index date
Fig. 1 Difference between men and women in subsite CRC among
people with T2D compared to people without diabetes
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free controls. However, differences regarding the location of
the CRC were observed. Compared to diabetes free controls,
men with T2D had a higher increased risk of distal colon
cancer than women with T2D, and women with T2D had a
higher increased risk of proximal colon cancer than men with
T2D. These findings remained after applying a 1-year lag
period to account for detection bias. Furthermore, women
with T2D aged ≥ 70 years are more likely to develop proximal
rather than distal colon cancer.
The overall risk of CRC observed in our study among
men and women with T2D compared to men and women
without diabetes is in line with previously published papers
[13, 15–17]. Several epidemiological studies presented
separate risks for proximal and distal colon cancer by sex
among people with T2D [11, 23–27], but also regardless of
diabetes [9, 28].
The majority of these studies among people with T2D
showed a higher increased risk of proximal colon cancer in
women with T2D (HR ranging from 1.6 to 1.8) than men with
T2D (HR ranging from 1.4 to 1.6) compared to diabetes free
controls, which is consistent with our finding [11, 23–25, 27].
One study [26] found, compared to diabetes free controls, a
higher increased risk of overall, proximal, and distal CRC
among men than women. However, men were almost twice
more likely to be classified as current or former cigarette
smoker and they believe effect modification from cigarette
smoking status appeared to have contributed to the difference
in risk observed by sex.
Our finding that, compared to diabetes free controls, men
are at higher risk to develop distal colon cancer than women
appears to be consistent with existing literature [11, 23–27].
Four of these studies [23, 25–27] found higher risks of distal
colon cancer among men (HR ranging from 1.3 to 2.1) than
women (HR ranging from 0.7 to 2.0). The other two studies
[11, 24] found a higher risk of distal colon cancer among
women than among men, but the results of these studies were
not statistically significant.
For rectal cancer, studies regarding its sex-specific associ-
ation with T2D are less consistent. One meta-analysis [29]
Table 2 Incident rates and hazard ratios of subsites of CRC among men and women with T2D and no diabetes
Men Women
T2D No diabetes T2DM vs. no diabetes T2D No diabetes T2DM vs. no diabetes
IR (95% CI) IR (95% CI) HRa (95% CI) IR (95% CI) IR (95% CI) HR* (95% CI)
Colon and rectum 1.66 (1.43–1.92) 1.31 (1.20–1.43) 1.26 (1.06–1.49) 1.21 (1.00–1.45) 0.95 (0.85–1.05) 1.33 (1.07–1.65)
Proximal 0.47 (0.35–0.61) 0.39 (0.33–0.45) 1.20 (0.87–1.65) 0.55 (0.41–0.72) 0.37 (0.31–0.44) 1.58 (1.13–2.19)
Cecum 0.17 (0.10–0.27) 0.17 (0.13–0.22) 0.96 (0.57–1.62) 0.23 (0.14–0.34) 0.17 (0.13–0.22) 1.37 (0.83–2.27)
Appendix – – – – – – – –
Ascending colon 0.21 (0.13–0.31) 0.10 (0.08–0.14) 2.12 (1.26–3.59) 0.18 (0.10–0.28) 0.10 (0.07–0.13) 1.98 (1.09–3.61)
Hepatic flexure 0.05 (0.02–0.12) 0.03 (0.01–0.05) 2.31 (0.83–6.48) 0.08 (0.04–0.16) 0.04 (0.02–0.07) 2.21 (0.92–5.32)
Transverse colon 0.04 (0.01–0.09) 0.08 (0.05–0.11) 0.41 (0.14–1.18) 0.06 (0.02–0.14) 0.05 (0.03–0.08) 1.22 (0.47–3.13)
Distal 0.66 (0.52–0.83) 0.46 (0.40–0.54) 1.42 (1.08–1.88) 0.26 (0.17–0.38) 0.29 (0.24–0.35) 0.86 (0.55–1.35)
Splenic flexure 0.01 (0.00–0.05) 0.02 (0.01–0.04) 0.30 (0.04–2.37) 0.06 (0.02–0.14) 0.03 (0.01–0.05) 2.39 (0.82–6.93)
Descending colon 0.07 (0.03–0.14) 0.03 (0.01–0.05) 2.56 (1.00–6.53) 0.02 (0.00–0.07) 0.03 (0.01–0.05) 0.60 (0.13–2.85)
Sigmoid colon 0.58 (0.44–0.74) 0.41 (0.35–0.48) 1.42 (1.05–1.91) 0.18 (0.10–0.28) 0.23 (0.19–0.29) 0.72 (0.42–1.24)
Rectum 0.46 (0.34–0.60) 0.42 (0.36–0.49) 1.06 (0.77–1.47) 0.33 (0.23–0.47) 0.26 (0.21–0.32) 1.33 (0.88–2.02)
a Adjusted for age, SES, and the use of aspirin, non-aspirin NSAIDs, statins, antihypertensives, and HRT in the year prior to index date
Fig. 2 Ratio of distal (including rectal)/proximal colon cancer for people
with T2D and no diabetes by age group among men (a) and women (b)
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found a statistically significant association between diabetes
and rectal cancer for men (HR (95% CI), 1.22 (1.07–1.40)),
but not for women (1.09 (0.99–1.19)). Two studies [25, 27]
found a statistically significant increased risk of rectal cancer
for women, which was higher than the non-statistically signif-
icant increased risk for men. Other cohort studies [10, 11, 23]
did not find a statistically significant association for men or
women, which was similar to our study.
In the general population, differences in the association
between sex and anatomic subsites of CRC have been ex-
plained by the fact that the proximal colon, distal colon, and
rectum have different embryological origins [30, 31]. In addi-
tion, hormonal factors, (epi) genetic differences, dietary fac-
tors, and structural factors have been proposed [9].
Furthermore, tumor suppressor genes, point mutations, genet-
ic instability, and responses of cells to growth stimulating
hormones, such as IGF, may differ by CRC subsite [11]. As
it is hypothesized that both diabetes and CRC involve over-
expression of both the insulin and IGF receptors [32], this
potentially even more complicates the association.
Epidemiological evidence also links hyperinsulinemia to
changes in sex steroids [33]. Sex differences in relation
to certain risk factors may modify risk for tumor develop-
ment, such as alcohol consumption, smoking, and red meat
consumption [31, 34]. All taken together, it is likely that all
these factors interact and act differently at various loca-
tions of the colorectum.
The results from our study suggest that sex-specific screen-
ing strategies are even more important among people with
diabetes. While women without diabetes are known to present
with proximal colon cancer more often than men, we found
that women with T2D have an even higher increased risk of
proximal colon cancer than women without diabetes.
Furthermore, women with T2D aged ≥ 70 years were even
more likely to be diagnosed with a proximal colon cancer than
with a distal colon cancer. More attention should be paid to the
adherence to colonoscopy screening in this risk group, being
better suited to detect lesions in the proximal colon than other
screening options.
Some limitations of this observational study should be
mentioned. First, possible important confounders, such as
obesity, smoking status, physical inactivity and nutritional in-
take could not be corrected for in our analyses. However,
previous epidemiological studies, presenting both crude and
adjusted risks, showed that adjusting for these factors only
slightly attenuated the risk. Second, only patients with a GP
recorded diagnosis or treated with blood glucose–lowering
drugs were included. Therefore, misclassification of T2D
could have occurred as some patients are undiagnosed [35].
Furthermore, detection bias is a common phenomenon.
People with T2D are more likely to be diagnosed with cancer
shortly after the onset of diabetes as compared to people with-
out diabetes. By applying a one-year lag period, we aimed to
exclude this bias, although the right lag period to exclude
detection bias remains unknown [10]. Finally, as only out-
come information regarding CRC was available, other forms
of cancer as competing outcomes could not be taken into
account. However, this will not affect the differences observed
between people with T2D compared to people without
diabetes.
Overall, this is the first study using the linkage between the
NCR and the GP Database of the PHARMO Database
Network for the association between T2D and sex- and site-
specific difference in CRC risk. By linking these databases, a
unique cohort was created taking advantage of the high-
quality data on cancer and detailed information regarding
T2D. This linkage resulted, to our knowledge, to one of the
largest, detailed cohorts of people with T2D in which the
incidence of subsite-specific CRC could be studied. An ad-
vantage of using the GP Database for selecting people with
T2D is including people with T2D not yet pharmacologically
treated (i.e., also people treated with lifestyle interventions).
The improved linkage gave us the opportunity to also analyze
the association between T2D and anatomical subsites of CRC.
Furthermore, ascertainment of exposure was based on large
and high-quality pharmaco-epidemiological databases, which
is more reliable than self-reported questionnaires. Because of
repeated information regarding exposure, patients’ follow-up
could be ended when (another type of) diabetes was diagnosed
(i.e., decreasing the likelihood of misclassification of T2D).
Conclusion
Besides a similarly increased risk of CRC among men and
women with T2D compared to diabetes free controls, we
found a higher increased risk of proximal colon cancer among
women with T2D than men with T2D and a higher increased
risk of distal colon cancer among men with T2D than women
with T2D, compared to diabetes free controls. Therefore, sex-
specific screening and prevention protocols may be consid-
ered for people with T2D. More tailored screening strategies
may optimize the effectiveness of CRC screening in terms of
reducing CRC incidence and mortality and improving the
quality of life. Furthermore, future studies investigating the
association between T2D and CRC should include sex-
specific and subsite-specific analyses.
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